

Technical Information Report

AAMI TIR48: 2015/(R)2021

Quality Management
System (QMS)
Recommendations on the
Application of the U.S.
FDA's CGMP Final Rule on
Combination Products

Published by

AAMI

901 N. Glebe Road, Suite 300

Arlington, VA 22203

www.aami.org

© 2015 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this document should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, et seq.) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, complete the reprint request form at www.aami.org or contact AAMI, 901 N. Glebe Road, Suite 300, Arlington, VA 22203. Phone: +1-703-525-4890; Fax: +1-703-525-1067.

Printed in the United States of America

ISBN 978-1-57020-590-3

This is a preview. [Click here to purchase the full publication.](#)

AAMI TIR48:2015/(R)2021

Quality Management System (QMS) Recommendations On the Application of the U.S. FDA's CGMP Final Rule on Combination Products

Approved 14 August 2015 and reaffirmed 26 March 2021 by
AAMI

Abstract:

This Technical Information Report (TIR) provides information on how to effectively implement FDA's regulation on Current Good Manufacturing Practices (CGMP) for combination products. Combination products are therapeutic or diagnostic medical products that combine drugs, devices, and/or biological products with one another, and the FDA regulation became effective July 22, 2013 (21 CFR Part 4). The TIR, where appropriate, also considers best practices, guidelines, and standards used both in the United States and other regions. The overall goal of the TIR is to aid informed, risk-based decisions in establishing CGMP operating systems that support development, manufacture, premarket regulatory evaluation, and ultimately commercialization of combination products. It should be noted that, while the information contained in the TIR has been carefully considered, it is up to the individual manufacturer to ensure compliance with all regulatory requirements that apply to its products.

Keywords:

CGMP for combination products, Combination product, Constituent part, Quality Systems, 21 CFR Part 4, 21 CFR Part 211, 21 CFR Part 820, 21 CFR Parts 600-680, 21 CFR Part 1271, CGMP, Design Controls, Risk management, Streamlined Approach, Single entity combination product, Co-packaged combination product, Cross-labeled combination product, FDA, Office of Combination Products (OCP), Management responsibility, Purchasing Controls, Corrective and preventive action (CAPA), Installation, Servicing, Component testing, Container testing, Closure testing, Calculation of yield, Tamper-evident packaging, Expiration dating, Release and distribution testing, Stability testing, Special testing, Reserve samples.

AAMI TECHNICAL INFORMATION REPORT

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 901 N. Glebe Road, Suite 300, Arlington, VA 22203.